Concepedia

Author

J. Miller

Universitair Ziekenhuis Leuven

Also Known As

J C Miller, J Miller, J. Miller, Joel C. Miller, Joel Miller

9

Publications

991

Citations

7

H-Index

19

Concepts

All Affiliations

Universitair Ziekenhuis LeuvenNovartis (United States)The Royal Melbourne HospitalUniversity of ManchesterWeston Park Cancer Centre
JM

About

J. Miller is an author at Universitair Ziekenhuis Leuven specializing in oncology, breast cancer, and pharmacotherapy.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

4

4

432

2

Health Sciences

3

3

154

3

Obstetrics

3

3

401

4

Pharmacology

3

3

154

5

Orthopaedics

1

1

63

J. Miller

×

7

Publications

988

Citations

7

H-Index

YearCitations

Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study

Holger Eidtmann, Richard de Boer, Nigel Bundred,

Annals of Oncology

2010

278

Effective inhibition of aromatase inhibitor‐associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole

Nigel Bundred, Ian Campbell, Neville Davidson,

Cancer

2008

216

Cardiac-Myocyte-Specific Excision of the Vinculin Gene Disrupts Cellular Junctions, Causing Sudden Death or Dilated Cardiomyopathy

Alice E. Zemljic‐Harpf, J. Miller, Scott A. Henderson,

Molecular and Cellular Biology

2007

210

Immediate Administration of Zoledronic Acid Reduces Aromatase Inhibitor–Associated Bone Loss in Postmenopausal Women With Early Breast Cancer: 12-Month Analysis of the E-ZO-FAST Trial

Antonio Llombart‐Cussac, Antonio Frassoldati, Outi Paija,

Clinical Breast Cancer

2011

130

Impact of Zoledronic Acid in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole: Z-FAST, ZO-FAST, and E-ZO-FAST.

Robert E. Coleman, N.J. Bundred, Richard de Boer,

Cancer Research

2009

63

The effect of zoledronic acid on aromatase inhibitor associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36 months follow-up of ZO-FAST.

Holger Eidtmann, N.J. Bundred, Rebecca DeBoer,

Cancer Research

2009

60

2008 POSTER The E-ZO-FAST trial: Zoledronic acid (ZA) effectively inhibits aromatase inhibitor associated bone loss (AIBL) in postmenopausal women (PMW) with early breast cancer (EBC) receiving adjuvant Letrozole (Let)

Natasha Schenk, A. Lombart, A. Frassoladti,

European Journal of Cancer Supplements

2007

31

Page 1